Sureskumar Desai, MD
Pulmonary Disease · Daytona Beach, FLNPI 1821181090
Payments from drug & device makers
Across 26 payments — averaging $154.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Boehringer Ingelheim$194
- Amgen$82
- Pulmonx Corporation$43
- Insmed, Inc.$40
- Paratek Pharmaceuticals, Inc.$34
- plus $135 from 6 others
What the payments were for
- Travel & lodging$48412%
- Food & beverage$51113%
- Education$3,03475%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $3,501 |
| Boehringer Ingelheim | 4 | $194 |
| Amgen | 4 | $82 |
| Pulmonx Corporation | 2 | $43 |
| Insmed, Inc. | 2 | $40 |
| Paratek Pharmaceuticals, Inc. | 2 | $34 |
| Inogen, Inc. | 1 | $29 |
| Vifor Pharma, Inc. | 1 | $28 |
| Tactile Systems Technology Inc | 1 | $23 |
| Pfizer | 1 | $22 |
| United Therapeutics Corporation | 1 | $18 |
| Electromed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$440
How this compares
$4,029 in reported general payments places this provider in the 45th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $105,072 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $33,875 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $22,924 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $12,914 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $12,841 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,023 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 90 | $3,786 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,524 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $1,195 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,079 |
| Prednisone | 15 | $37 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Daytona Beach
- Dany ObeidDaytona Beach$584K
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.